Anbio Biotechnology is a US-listed company in the health care equipment industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: valuation models disagree too widely to rate.
Under review: valuation models disagree too widely to rate. We'll show the comparison once resolved.
Anbio Biotechnology valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months was $9m. The diluted share count is up 3.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 2 financial-health checks.
Our model value for Anbio Biotechnology is under review, so past values are not shown until it is resolved.
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Where it stands out: operating margin of 66.7% ranks 1 of 132 health care equipment companies we cover. Where it lags: days sales outstanding of 154 days ranks 116 of 118 health care equipment companies we cover.
Current signal Net margin expanding: TTM net margin reached 74.1%, up 45.1pp year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for NNNN from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Anbio Biotechnology as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | ~$2.7 ~$2.8–$5.0 | Primary model, counts double |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | ~$6.1 ~$4.3–$8.8 | Included |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | ~$3.4 ~$2.9–$4.0 | Included |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Anbio Biotechnology with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2025 |
|---|---|
| Share price | $30.07 |
| Market value | $1.3bn |
| + Net debt (− = net cash) | −$8m |
| Enterprise value | $1.3bn |
| Multiples | |
| Price / sales | 151.9x |
| Price / earnings | n/m |
| Price / free cash flow | — |
| EV / EBITDA | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
No analyst estimates are published for Anbio Biotechnology: too few analysts cover it.
| Calendar year | 2026 to date |
|---|---|
| Return | |
| NNNN | −88% |
| Industry peers (median) | −13% |
| S&P 500 | +11% |
| Months that ended higher | |
| NNNN | 36% |
| S&P 500 | 46% |
| Largest fall from a high during the year | |
| NNNN | −92% |
| S&P 500 | −9% |
Worst fall since February 19, 2025: 94% from August 19, 2025 to October 16, 2026. Getting back needed a 1565% gain, and the shares have not yet recovered.
Source: SEC EDGAR filings. Retrieved Invalid Date.
| Period | Revenue (TTM) |
|---|---|
| FY22 Q4 | $23.5M |
| FY23 Q4 | $6.7M |
| FY24 Q4 | $8.2M |
| FY25 Q4 | $8.6M |
Source: SEC EDGAR filings. Retrieved Invalid Date.
| Period | Operating margin (TTM) |
|---|---|
| FY22 Q4 | 43.3% |
| FY23 Q4 | 29.2% |
| FY24 Q4 | 24.4% |
| FY25 Q4 | 66.7% |
Each dollar Anbio Biotechnology took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.
| Revenue | $8.6M | |
|---|---|---|
| Other income | $635,723 | 7.4% of revenue |
| Cost of revenue | $1.1M | 12.8% of revenue |
| Gross profit | $7.5M | 87.2% of revenue |
| Research and development | $201,305 | 2.3% of revenue |
| Selling, general and admin | $1.6M | 18.2% of revenue |
| Operating income | $5.8M | 66.7% of revenue |
| Net income | $6.4M | 74.1% of revenue |
| Fiscal year | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|---|
| Income | ||||
| Revenue | 24 | 7 | 8 | 9 |
| Gross profit | 13 | 3 | 6 | 8 |
| Operating income | 10 | 2 | 2 | 6 |
| Net income | 10 | 2 | 2 | 6 |
| Diluted EPS | $50056.00 | $0.05 | $0.06 | $0.15 |
| Growth (year on year) | ||||
| Revenue | — | −71.5% | +21.9% | +5.6% |
| Operating income | — | −80.8% | +1.8% | +189.1% |
| Net income | — | −77.5% | +5.3% | +169.9% |
| Diluted EPS | — | −100.0% | +6.7% | +162.5% |
| Margins | ||||
| Gross margin | 53.4% | 50.1% | 71.9% | 87.2% |
| Operating margin | 43.3% | 29.2% | 24.4% | 66.7% |
| Net margin | 42.5% | 33.6% | 29.0% | 74.1% |
| Cash flow | ||||
| Cash from operations | 4 | 1 | 2 | −7 |
| Balance sheet | ||||
| Cash | 7 | 10 | 12 | 8 |
| Total debt | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −7 | −10 | −12 | −8 |
| Diluted shares | — | 43m | 42m | 44m |
| Last 12 months unless stated | NNNN | NUWE | MLSS | NMTC | XAIR | WOK | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $9m | $9m | $9m | $9m | $8m | $10m | $99m |
| Revenue growth, last 12 months | 5.6% | 8.4% | 3.7% | 42.8% | 60.7% | −14.4% | 9.2% |
| Revenue growth, 3-year average | — | 2.8% | −1.9% | 94.9% | 122.7% | — | 13.5% |
| Revenue growth, latest quarter | — | 14.1% | 22.3% | 16.3% | 0.5% | — | 10.2% |
| Gross margin | 87.2% | 69.7% | 70.2% | 55.6% | 4.2% | 23.8% | 61.2% |
| Operating margin | 66.7% | −142.9% | −43.6% | −83.4% | −364.8% | — | −8.5% |
| Operating margin, 3-year average | — | −138.4% | −66.8% | −160.3% | <−999% | — | −17.9% |
| Net margin | 74.1% | −125.6% | −44.0% | −78.6% | −435.7% | −10.9% | −12.0% |
| Cash from operations / revenue | −77.9% | −138.3% | −6.8% | −74.5% | −241.5% | 63.4% | −1.9% |
| Free-cash-flow margin | — | −139.7% | −7.0% | −75.6% | −255.0% | 49.9% | −3.9% |
| Free-cash-flow margin, 3-year average | — | −126.7% | −53.1% | −142.5% | <−999% | — | −7.0% |
| Stock pay / revenue | — | 1.0% | 10.3% | 14.9% | 61.7% | — | 6.1% |
| Change in share count | 3.3% | 5.4% | 5.9% | 41.1% | −99.0% | 128.1% | 4.0% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 5.6% | 9.1% | 79 of 129 |
| Change in growth rate Growth | -16.3pp | -0.6pp | 114 of 129 |
| Gross margin Profitability | 87.2% | 61.9% | 7 of 123 |
| Operating margin Profitability | 66.7% | -8.3% | 1 of 132 |
| Net margin Profitability | 74.1% | -12.0% | 1 of 133 |
| Change in share count Balance sheet | 3.3% | 3.3% | 57 of 115 |
| Days sales outstanding Balance sheet | 154 days | 57 days | 116 of 118 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Geode Capital Management, LLC | $366,550 | 27K | 37.2% | ▲ 3.8% |
| Bank Of America Corp | $183,974 | 13K | 18.7% | New |
| BNP Paribas Financial Markets | $161,778 | 12K | 16.4% | ▲ 13.5% |
| Marshall Wace, LLP | $157,692 | 12K | 16.0% | New |
| Morgan Stanley | $99,137 | 7K | 10.1% | ▼ 1.5% |
| UBS Group AG | $11,352 | 1K | 1.2% | ▼ 86.9% |
| Eversource Wealth Advisors, LLC | $2,564 | 0K | 0.3% | ▼ 29.7% |
| Osaic Holdings, Inc. | $1,056 | 0K | 0.1% | New |
| Jpmorgan Chase & Co | $718 | 0K | 0.1% | New |
| Bare Financial Services, Inc | $206 | 0K | 0.0% | 0.0% |
| Larson Financial Group LLC | $69 | 0K | 0.0% | New |
| Silver Grove Financial Group, Inc. | $55 | 0K | 0.0% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Anbio Biotechnology's complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
